Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2

• Published in: Clinical lipidology Vol. 12; no. 1; pp. 56 - 109
• Main Authors: Iyengar, S. S., Puri, R., Narasingan, S. N., Nair, D. R., Mehta, V., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., Jha, V., Puri, S., Misra, A., Daga, M. K., Varma, M., Jasuja, S., Upadhyaya, S., Kasliwal, R. R., Bansal, M., Mehrotra, R., Jain, A., Talwar, K. K., Rajput, R., Pradhan, A., Seth, S., Kapoor, D., Melinkeri, R. P., Ramakrishnan, S., Khanna, N. N., Khadgawat, R., Shaikh, A., Kovalipati, N., Bordoloi, N., Zargar, A. H., Agarwal, R. K., Rastogi, A., Chag, M., Prabhakar, D., Mathur, S. K., Rehan, H., Sahoo, P. K., Dutta, A., Sharma, A., Pancholia, A. K., Natarajan, K. U., Mishra, A., Singh, K.
• Format: Journal Article
• Language: English
• Published: London Taylor & Francis 01.12.2017; Taylor & Francis Ltd
• Subjects: 4D: Die Deutsche Diabetes Dialyses Studie; ABCD: Amsterdam Born Children and Their Development; ACC: American College of Cardiology; ACCF: American College of Cardiology Foundation; ACCORD: Action to Control Cardiovascular Risk in Diabetes; AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention study; AHA: American Heart Association; AIM-HIGH: Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglyceride; ALA: Alpha Linolenic Acid; ALERT: Assessment of Lescol in Renal Transplantation; ALT: Alanine Aminotransferase; Apo A: Apolipoprotein A; Apo B: Apolipoprotein B; Apo C: Apolipoprotein C; Apo E: Apolipoprotein E; AS: Ankylosing Spondylitis; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm; ASCVD: Atherosclerotic Cardiovascular Disease; AST: Aspartate Aminotransferase; AURORA: A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; bDMARDs: Biological Disease Modifying Anti-Rheumatic Drugs; BNP: Brain Natriuretic Peptide; CAD: Coronary Artery Disease; CARDS: Collaborative Atorvastatin Diabetes Study; CARE: Cholesterol and Recurrent Events; CAV: Cardiac Allograft Vasculopathy; cDMARDs: Conventional Disease Modifying Anti-Rheumatic Drugs; CETP: Cholesteryl Ester Transfer Protein; cIMT: Carotid Intima Media Thickness; CK: Creatine Kinase; CKD: Chronic Kidney Disease; Co-Q10: Coenzyme Q10; CORONA: Controlled Rosuvastatin Multinational Study in Heart Failure; COX-2: Cyclooxygenase-2; CRP: C-Reactive Protein; csDMARDs: Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs; CTT: Cholesterol Treatment Trialists; CV: Cardiovascular; CVD: Cardiovascular Disease; DHA: Docosahexaenoic Acid; DM: Diabetes Mellitus; DMARDs: Disease Modifying Anti-Rheumatic Drugs; DOPPS: Dialysis Outcome and Practice Patterns Study; eGFR: Estimated Glomerular Filtration Rate; EPA: Eicosapentaenoic Acid; ESRD: End Stage Renal Disease; FDA: Food and Drug Administration; FH: Familial Hypercholesterolaemia; FIELD: Fenofibrate Intervention and Event Lowering in Diabetes; FOURIER: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; GISSI-HF: GruppoItaliano per lo Studio dellaSopravvivenzanell'InfartoMiocardico Heart Failure; GPIHBP: Glycosylphosphatidyl Inositol Anchoring High-Density Lipoprotein Binding Protein; GREACE: Greek Atorvastatin and Coronary Heart Disease Evaluation; HDL-C: High-Density Lipoprotein Cholesterol; HDL: High-Density Lipoprotein; HeFH: Heterozygous FH; HF: Heart Failure; HIV: Human Immunodeficiency Virus; HMG CoA reductase: 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme a Reductase; HoFH: Homozygous FH; HPS2-THRIVE: Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events; HPS: Heart Protection Study; HR: Hazard Ratio; HRT: Hormone Replacement Therapy; hsCRP: High sensitivity C-Reactive Protein; ICH: Intracerebral Haemorrhage; IDL: Intermediate Density Lipoprotein; IJD: Inflammatory joint disorder; IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trial; India; JBS: Joint British Society; JELIS: Japan EPA Lipid Intervention Study; JUPITER: Justification for the use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin; KDIGO: Kidney Disease: Improving Global Outcomes; Kidney diseases; LAI: Lipid Association of India; LDL-C: Low-Density Lipoprotein Cholesterol; LDL: Low-Density Lipoprotein; LDLR: Low-Density Lipoprotein Receptor; LIPID: Long-Term Intervention with Pravastatin in Ischemic Disease; Lipids; LMF: Lipase Maturation factor; Lp(a): Lipoprotein (a); LPL: Lipoprotein Lipase; LVEF: Left Ventricular Ejection Fraction; MEDPED: Make Early Diagnosis to Prevent Early Deaths; MEGA: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; Metabolic disorders; MetS: Metabolic Syndrome; MHC: Major Histocompatibility Complex; MI: Myocardial Infarction; mTOR: Mammalian Target Of Rapamycin; NAFLD: Non-alcoholic Fatty Liver Disease; NASH: Non-alcoholic Steatohepatitis; NICE: National Institute for Health and Care Excellence; NLA: National Lipid Association; NNT: Number Needed to Treat; Non-HDL-C: Non-High-density Lipoprotein Cholesterol; NSAID: Non-Steroidal Anti-Inflammatory Drug; NT-proBNP: N-Terminal pro-Brain Natriuretic Peptide; NYHA: New York Heart Association; OCP: Oral Contraceptive Pill; ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome During Treatment With Alirocumab; Older people; PCOS: Polycystic Ovary Syndrome; PCSK9: Proprotein Convertase Subtilisin Kexin Type 9; Populations; PPAR: Peroxisome Proliferator-Activated Receptor; PRECISION: Prospective Randomised Evaluation of Celecoxib Integrated Safety VS Ibuprofen or Naproxen; PROSPER: Prospective Study of Pravastatin in the Elderly at Risk; PsA: Psoriatic Arthritis; RA: Rheumatoid Arthritis; RCT: Randomised Controlled Trial; Recommendation; RR: Relative Risk; SAGE: Study Assessing Goals in the Elderly; SHEP: Systolic Hypertension in the Elderly Program; specific populations; T2DM: Type 2 DiabetesMellitus; TG: Triglyceride; THRaST: THRombolysis and STatins; TNT: Treating to New Targets; TRACE-RA: Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with RA; Transplantation; tsDMARDs: Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs; TSH: Thyroid Stimulating Hormone; ULN: Upper Limit of Normal; Viruses; VLDL-C: Very Low-density Lipoprotein cholesterol; VLDL: Very Low-density Lipoprotein; WHO: World Health Organization; WOSCOPS: West of Scotland Coronary Prevention Study; India
• ISSN: 1758-4299; 1758-4302; 2641-5321
• DOI: 10.1080/17584299.2017.1383700

These Lipid Association of India (LAI) recommendations refer to specific patient populations. They follow the previously published LAI part 1 recommendations. These part 2 LAI recommendations focus on specific patient groups. These include patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection. We also consider women, the elderly and post-transplantation patients. The current recommendations are based, as much as possible, on available data from Indian populations.